Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2020 16:05 ET | Source: Prevail Therapeutics

Prevail Therapeutics to Present at Bank of America Global Research Virtual Health Care Conference 2020

NEW YORK, May 05, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene...
April 29, 2020 09:09 ET | Source: Prevail Therapeutics

Prevail Therapeutics to Highlight Multiple CNS-Focused Gene Therapy Programs at 2020 American Society of Gene & Cell Therapy Annual Meeting

Preclinical Data Demonstrate Potential of Prevail’s AAV Gene Therapy Approach to Slow or Halt Progression in Multiple Neurodegenerative Diseases Company Provides Design Overview for Planned Phase 1/2...
March 31, 2020 07:00 ET | Source: Prevail Therapeutics

Prevail Therapeutics to Present at AAT-AD/PD Focus Meeting 2020: Advances in Alzheimer’s and Parkinson’s Therapies

Design of PROPEL Phase 1/2 Clinical Trial for Parkinson’s Disease Patients with GBA1 Mutations to Be Presented Preclinical Data of PR001 for Parkinson’s Disease with GBA1 Mutations and PR006 for...
March 26, 2020 07:00 ET | Source: Prevail Therapeutics

Prevail Therapeutics Reports Full Year 2019 Financial Results and Business Highlights

Dosing Initiated in PROPEL Phase 1/2 Trial of PR001 for Treatment of Parkinson’s Disease with GBA1 Mutations Preparations Underway to Initiate PROVIDE Phase 1/2 Trial of PR001 for Treatment of Type...
March 24, 2020 07:00 ET | Source: Prevail Therapeutics

Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR006 to Slow the Progression of Frontotemporal Dementia with a GRN Mutation

NEW YORK, March 24, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
March 03, 2020 07:00 ET | Source: Prevail Therapeutics

Prevail Therapeutics Provides Clinical Advancement Update on PR001 for the Treatment of Parkinson’s Disease with GBA1 mutations

NEW YORK, March 03, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
March 02, 2020 07:00 ET | Source: Prevail Therapeutics

Prevail Therapeutics Announces Investigational New Drug Application Active for PR006 for the Treatment of Frontotemporal Dementia with GRN Mutation

NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
February 21, 2020 08:30 ET | Source: Prevail Therapeutics

Prevail Therapeutics to Present at Upcoming Conferences

NEW YORK, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene...
February 12, 2020 07:00 ET | Source: Prevail Therapeutics

Prevail Therapeutics’ PR001 Receives Orphan Drug Designation and Rare Pediatric Disease Designation from FDA

Orphan Drug Designation Granted for Treatment of Gaucher Disease Rare Pediatric Disease Designation Granted for Treatment ofNeuronopathic Gaucher Disease NEW YORK, Feb. 12, 2020 (GLOBE...
February 06, 2020 08:30 ET | Source: Prevail Therapeutics

Prevail Announces Presentations at the 16th Annual WORLDSymposium™ 2020

NEW YORK, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or the “Company”), a biotechnology company developing potentially disease-modifying AAV-based gene...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right